Key considerations in navigating ticagrelor's reported effect on heparin-induced thrombocytopenia functional assays in a landscape of limited data.

This article examines the potential for ticagrelor, an antiplatelet medication, to cause false-negative results in functional assays used to diagnose heparin-induced thrombocytopenia (HIT), a serious prothrombotic condition. Limited data suggest ticagrelor may interfere with tests such as the heparin-induced platelet activation (HIPA) and serotonin release assay (SRA), leading to diagnostic challenges and possible clinical risks. The article highlights current gaps in research, recommends cautious interpretation of functional assay results in patients receiving ticagrelor, and proposes management strategies including temporary ticagrelor withdrawal, use of alternative P2Y12 inhibitors, and reliance on immunoassay results combined with clinical scoring systems like the 4Ts score. It also emphasizes the need for further studies to clarify ticagrelor's impact on various HIT assays and to develop improved diagnostic algorithms.